Merck & Co., Inc: Colitis, Ulcerative trials
The registry lists 13 Colitis, Ulcerative studies with Merck & Co., Inc as lead sponsor. 2 are open to participants now and 8 have results posted.
Phase 1 2Phase 2 2Phase 3 4Phase 4 3No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)RecruitingNCT07463183Phase 2
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)RecruitingNCT06651281Phase 3
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)CompletedNCT04996797Phase 2Results posted
- A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)CompletedNCT04924114Phase 1Results posted
- Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).CompletedNCT02318667Phase 4Results posted
- Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)CompletedNCT02155335Phase 4Results posted
- Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)CompletedNCT02092285Phase 4Results posted
- Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)TerminatedNCT00984568Phase 3Results posted
- European Safety Registry in Ulcerative Colitis (P04808)CompletedNCT00705484Results posted
- Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)TerminatedNCT00537316Phase 3Results posted
- Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)CompletedNCT06829225Phase 1
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Active, not recruitingNCT06052059Phase 3
- Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)WithdrawnNCT01293656